[Current update on PCKS9 inhibitors].

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Proprotein convertase subtilisin kexin 9 (PCSK9) monoclonal antibodies (mAb) represent a novel therapeutic class for managing hypercholesterolemia.
• Elevated LDL-cholesterol is a primary risk factor for atherosclerotic cardiovascular disease (ASCVD).

Purpose of the Study:

• To evaluate the efficacy and clinical utility of PCSK9 mAb in lowering LDL-cholesterol and reducing cardiovascular events.
• To define the patient populations who may benefit most from PCSK9 mAb therapy.

Main Methods:

• Analysis of data from large-scale clinical trials investigating PCSK9 mAb efficacy.
• Review of current clinical guidelines and reimbursement policies for PCSK9 mAb in Switzerland.

Main Results:

• PCSK9 mAb demonstrate significant LDL-cholesterol lowering capabilities.
• Addition of PCSK9 mAb to statin therapy reduces major adverse cardiovascular events in high-risk ASCVD patients.
• Alirocumab and evolocumab are available but have specific reimbursement limitations.

Conclusions:

• PCSK9 mAb are valuable therapeutic options for patients with clinical ASCVD or familial hypercholesterolemia with high LDL-C levels.
• Consideration of PCSK9 mAb is warranted for patients with statin intolerance or inadequate response to maximally tolerated statin therapy.
• Careful patient selection is crucial given current reimbursement restrictions.